EGFR expression and gene copy number in triple-negative breast carcinoma

Cancer Genetics and Cytogenetics

Volumn 203, Issue 2, 2010, Pages 222-229

  Gumuskaya, Berrak ^a,b   Alper, Murat ^a   Hucumenoglu, Sema ^a   Altundag, Kadri ^b   Uner, Aysegul ^b   Guler, Gulnur ^b,c  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CHROMOSOME 7; CONTROLLED STUDY; DISOMY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CYTOPLASM; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78650010086     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.07.118     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Rakha E.A., El-Rehim D.A., Paish C., Green A.R., Lee A.H., Robertson J.F., et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006, 42:3149-3156.
3. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
4. Fulford L.G., Easton D.F., Reis-Filho J.S., Sofronis A., Gillett C.E., Lakhani S.R., et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006, 49:22-34.
5. Siziopikou K.P., Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007, 16:104-107.
6. Livasy C.A., Karaca G., Nanda R., Tretiakova M.S., Olopade O.I., Moore D.T., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19:264-271.
7. Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376.
8. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
9. Rakha E.A., Tan D.S., Foulkes W.D., Ellis I.O., Tutt A., Nielsen T.O., et al. Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res 2007, 9:404.
10. Vokes E.E., Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 2006, 20:15-25.
11. Hirsch F.R., Varella-Garcia M., Bunn P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
12. Bhargava R., Gerald W.L., Li A.R., Pan Q., Lal P., Ladanyi M., et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005, 18:1027-1033.
13. Reis-Filho J.S., Pinheiro C., Lambros M.B., Milanezi F., Carvalho S., Savage K., et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006, 209:445-453.
14. Gilbert J.A., Goetz M.P., Reynolds C.A., Ingle J.N., Giordano K.F., Suman V.J., et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther 2008, 7:944-951.
15. Gwin K, Lezon-Geyda K, Harris L, Tavassoli FA. Chromosome 7 aneusomy in metaplastic breast carcinomas with chondroid, squamous, and spindle-cell differentiation. Int J Surg Pathol (In press).
16. Toyama T., Yamashita H., Kondo N., Okuda K., Takahashi S., Sasaki H., et al. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 2008, 8:309.
17. Tavassoli F.A., Devilee P. Pathology and genetics of the breast and female genital organs. World Health Organization classification of tumours 2003, IARC Press, Lyon.
18. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:643-655.
19. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
20. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
21. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
22. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006, 24:3340-3346.
23. Sunaga N., Tomizawa Y., Yanagitani N., Iijima H., Kaira K., Shimizu K., et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007, 56:383-389.
24. Sutani A., Nagai Y., Udagawa K., Uchida Y., Koyama N., Murayama Y., et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006, 95:1483-1489.
25. Li A.R., Chitale D., Riely G.J., Pao W., Miller V.A., Zakowski M.F., et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008, 10:242-248.
26. Hirsch F.R., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007, 18:752-760.
27. Hirsch F.R., Herbst R.S., Olsen C., Chansky K., Crowley J., Kelly K., et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008, 26:3351-3357.
28. Zakowski M.F., Hussain S., Pao W., Ladanyi M., Ginsberg M.S., Heelan R., et al. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med 2009, 133:470-477.
29. Ekstrand A.J., Sugawa N., James C.D., Collins V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 1992, 89:4309-4313.
30. Gouvea A.P., Milanezi F., Olson S.J., Leitao D., Schmitt F.C., Gobbi H. Selecting antibodies to detect HER-2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol 2006, 14:103-108.